<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:35:37Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9636507" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9636507</identifier>
        <datestamp>2022-11-07</datestamp>
        <setSpec>canmed</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="cam44724" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Cancer Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id>
              <journal-id journal-id-type="publisher-id">CAM4</journal-id>
              <journal-title-group>
                <journal-title>Cancer Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2045-7634</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9636507</article-id>
              <article-id pub-id-type="pmcid">PMC9636507</article-id>
              <article-id pub-id-type="pmc-uid">9636507</article-id>
              <article-id pub-id-type="pmid">35396812</article-id>
              <article-id pub-id-type="pmid">35396812</article-id>
              <article-id pub-id-type="doi">10.1002/cam4.4724</article-id>
              <article-id pub-id-type="publisher-id">CAM44724</article-id>
              <article-id pub-id-type="other">CAM4-2021-11-4783.R2</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>RESEARCH ARTICLES</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Clinical Cancer Research</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A phase I study of talazoparib (<styled-content style="fixed-case" toggle="no">BMN</styled-content> 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (<styled-content style="fixed-case" toggle="no">NCI9782</styled-content>)</article-title>
                <alt-title alt-title-type="left-running-head">Leal et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="cam44724-cr-0001" contrib-type="author">
                  <name>
                    <surname>Leal</surname>
                    <given-names>Ticiana A.</given-names>
                  </name>
                  <xref rid="cam44724-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0002" contrib-type="author">
                  <name>
                    <surname>Sharifi</surname>
                    <given-names>Marina N.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0128-3033</contrib-id>
                  <xref rid="cam44724-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0003" contrib-type="author">
                  <name>
                    <surname>Chan</surname>
                    <given-names>Nancy</given-names>
                  </name>
                  <xref rid="cam44724-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0004" contrib-type="author">
                  <name>
                    <surname>Wesolowski</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <xref rid="cam44724-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0005" contrib-type="author">
                  <name>
                    <surname>Turk</surname>
                    <given-names>Anita A.</given-names>
                  </name>
                  <xref rid="cam44724-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0006" contrib-type="author">
                  <name>
                    <surname>Bruce</surname>
                    <given-names>Justine Y.</given-names>
                  </name>
                  <xref rid="cam44724-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0007" contrib-type="author">
                  <name>
                    <surname>O'Regan</surname>
                    <given-names>Ruth M.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6984-3741</contrib-id>
                  <xref rid="cam44724-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0008" contrib-type="author">
                  <name>
                    <surname>Eickhoff</surname>
                    <given-names>Jens</given-names>
                  </name>
                  <xref rid="cam44724-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0009" contrib-type="author">
                  <name>
                    <surname>Barroilhet</surname>
                    <given-names>Lisa M.</given-names>
                  </name>
                  <xref rid="cam44724-aff-0008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0010" contrib-type="author">
                  <name>
                    <surname>Malhotra</surname>
                    <given-names>Jyoti</given-names>
                  </name>
                  <xref rid="cam44724-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0011" contrib-type="author">
                  <name>
                    <surname>Mehnert</surname>
                    <given-names>Janice</given-names>
                  </name>
                  <xref rid="cam44724-aff-0009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0012" contrib-type="author">
                  <name>
                    <surname>Girda</surname>
                    <given-names>Eugenia</given-names>
                  </name>
                  <xref rid="cam44724-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0013" contrib-type="author">
                  <name>
                    <surname>Wiley</surname>
                    <given-names>Elizabeth</given-names>
                  </name>
                  <xref rid="cam44724-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0014" contrib-type="author">
                  <name>
                    <surname>Schmitz</surname>
                    <given-names>Natalie</given-names>
                  </name>
                  <xref rid="cam44724-aff-0010" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0015" contrib-type="author">
                  <name>
                    <surname>Andrews</surname>
                    <given-names>Shannon</given-names>
                  </name>
                  <xref rid="cam44724-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0016" contrib-type="author">
                  <name>
                    <surname>Liu</surname>
                    <given-names>Glenn</given-names>
                  </name>
                  <xref rid="cam44724-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cam44724-cr-0017" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Wisinski</surname>
                    <given-names>Kari B.</given-names>
                  </name>
                  <xref rid="cam44724-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <address>
                    <email>kbwisinski@medicine.wisc.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="cam44724-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Winship Cancer Institute</named-content>
                <institution>Emory University</institution>
                <country country="GE">Georgia</country>
              </aff>
              <aff id="cam44724-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>University of Wisconsin Carbone Cancer Center</institution>
                <city>Madison</city>
                <named-content content-type="country-part">Wisconsin</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cam44724-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <institution>Rutgers Cancer Institute of New Jersey</institution>
                <city>New Brunswick</city>
                <named-content content-type="country-part">New Jersey</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cam44724-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <institution>Ohio State University Comprehensive Cancer Center</institution>
                <city>Columbus</city>
                <named-content content-type="country-part">Ohio</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cam44724-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <institution>Indiana University Simon Comprehensive Cancer Center</institution>
                <city>Indianapolis</city>
                <named-content content-type="country-part">Indiana</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cam44724-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>University of Rochester</institution>
                <city>Rochester</city>
                <named-content content-type="country-part">New York</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cam44724-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">Department of Biostatistics</named-content>
                <institution>University of Wisconsin School of Medicine and Public Health</institution>
                <city>Madison</city>
                <named-content content-type="country-part">Wisconsin</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cam44724-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <named-content content-type="organisation-division">Department of Obstetrics and Gynecology</named-content>
                <institution>University of Wisconsin School of Medicine and Public Health</institution>
                <city>Madison</city>
                <named-content content-type="country-part">Wisconsin</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cam44724-aff-0009">
                <label>
                  <sup>9</sup>
                </label>
                <named-content content-type="organisation-division">Perlmutter Cancer Center</named-content>
                <institution>New York University Grossman School of Medicine</institution>
                <city>New York</city>
                <named-content content-type="country-part">New York City</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cam44724-aff-0010">
                <label>
                  <sup>10</sup>
                </label>
                <named-content content-type="organisation-division">School of Pharmacy</named-content>
                <institution>University of Wisconsin</institution>
                <city>Madison</city>
                <named-content content-type="country-part">Wisconsin</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Dr. Kari B. Wisinski, UW Carbone Cancer Center, University of Wisconsin, Madison, 1111 Highland Avenue, WIMR 6033, Madison, WI 53705 USA.<break/>
Email: <email>kbwisinski@medicine.wisc.edu</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>08</day>
                <month>4</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>11</month>
                <year>2022</year>
              </pub-date>
              <volume>11</volume>
              <issue seq="60">21</issue>
              <issue-id pub-id-type="doi">10.1002/cam4.v11.21</issue-id>
              <fpage>3969</fpage>
              <lpage>3981</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>21</day>
                  <month>2</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>13</day>
                  <month>11</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>13</day>
                  <month>3</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2022 Published by John Wiley & Sons Ltd.-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">Cancer Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:CAM4-11-3969.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="cam44724-sec-0001">
                  <title>Background</title>
                  <p>Inhibitors of poly(ADP‐ribose) polymerase (PARP) proteins potentiate antitumor activity of platinum chemotherapy. This study sought to determine the safety and tolerability of PARP inhibitor talazoparib with carboplatin and paclitaxel.</p>
                </sec>
                <sec id="cam44724-sec-0002">
                  <title>Methods</title>
                  <p>We conducted a phase I study of talazoparib with carboplatin AUC5‐6 and paclitaxel 80 mg/m<sup>2</sup> days 1, 8, 15 of 21‐day cycles in patients with advanced solid tumors. Patients enrolled using a 3 + 3 design in two cohorts with talazoparib for 7 (schedule A) or 3 days (schedule B). After induction with 4–6 cycles of triplet therapy, patients received one of three maintenance options: (a) continuation of triplet (b) carboplatin/talazoparib, or (c) talazoparib monotherapy.</p>
                </sec>
                <sec id="cam44724-sec-0003">
                  <title>Results</title>
                  <p>Forty‐three patients were treated. The MTD for both schedules was talazoparib 250mcg daily. The main toxicity was myelosuppression including grade 3/4 hematologic treatment‐related adverse events (TRAEs). Dose modification occurred in 87% and 100% of patients for schedules A and B, respectively. Discontinuation due to TRAEs was 13% in schedule A and 10% in B. Ten out of 22 evaluable patients in schedule A and 5/16 patients in schedule B had a complete or partial response. Twelve out of 43 patients received ≥6 cycles of talazoparib after induction, with a 13‐month median duration of maintenance.</p>
                </sec>
                <sec id="cam44724-sec-0004">
                  <title>Conclusion</title>
                  <p>We have established the recommended phase II dose of Talazoparib at 250mcg on a 3‐ or 7‐day schedule with carboplatin AUC6 and paclitaxel 80 mg/m<sup>2</sup> on days 1, 8, 15 of 21‐day cycles. This regimen is associated with significant myelosuppression, and in addition to maximizing supportive care, modification of the chemotherapy component would be a consideration for further development of this combination with the schedules investigated in this study.</p>
                </sec>
              </abstract>
              <abstract abstract-type="graphical">
                <p>Carboplatin, paclitaxel and talazoparib followed by talazoparib maintenance is feasible with appropriate supportive care, and warrants further investigation across solid tumor types, particularly those with DNA repair pathway alterations, and supports further development of PARP inhibitor maintenance strategies in the advanced disease setting.<boxed-text position="anchor" content-type="graphic" id="cam44724-blkfxd-0001"><graphic xlink:href="CAM4-11-3969-g001.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="cam44724-kwd-0001">BMN673</kwd>
                <kwd id="cam44724-kwd-0002">carboplatin</kwd>
                <kwd id="cam44724-kwd-0003">paclitaxel</kwd>
                <kwd id="cam44724-kwd-0004">PARP</kwd>
                <kwd id="cam44724-kwd-0005">talazoparib</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Cancer Institute
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000054</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>P30CA014520</award-id>
                  <award-id>UM1CA186691</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="6"/>
                <page-count count="13"/>
                <word-count count="6726"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>November 2022</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.0 mode:remove_FC converted:05.11.2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="CAM44724-cit-2001"><string-name><surname>Leal</surname><given-names>TA</given-names></string-name>, <string-name><surname>Sharifi</surname><given-names>MN</given-names></string-name>, <string-name><surname>Chan</surname><given-names>N</given-names></string-name>, et al. <article-title>A phase I study of talazoparib (<styled-content style="fixed-case" toggle="no">BMN</styled-content> 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (<styled-content style="fixed-case" toggle="no">NCI9782</styled-content>)</article-title>. <source>Cancer Med</source>. <year>2022</year>;<volume>11</volume>(21):<fpage>3969</fpage>‐<lpage>3981</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cam4.4724</pub-id>
</mixed-citation>
              </p>
              <fn-group id="cam44724-ntgp-0001">
                <fn id="cam44724-note-0001">
                  <p>Ticiana A. Leal and Marina. N. Sharifi contributed equally.</p>
                </fn>
                <fn id="cam44724-note-0002">
                  <p>
                    <bold>Funding information</bold>
                  </p>
                  <p>Supported by UW Comprehensive Cancer Center Support Grant (CCSG) (P30CA014520) and The John Hopkins Translational Science Team and Consortium for ETCTN Studies (UM1CA186691).</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="cam44724-body-0001">
            <sec id="cam44724-sec-0005">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Poly (ADP‐ribose) polymerase (PARP) 1 and 2 are nuclear enzymes that play a crucial role in initiating the DNA damage response (DDR) to maintain genomic integrity.<xref rid="cam44724-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="cam44724-bib-0002" ref-type="bibr"><sup>2</sup></xref> Inhibition of PARP1/2 leads to the accumulation of single strand breaks, causing double strand breaks that require repair by homologous recombination (HR), and tumor cells lacking BRCA1 or BRCA2, which play key roles in the HR pathway, are uniquely sensitive to PARP inhibition.<xref rid="cam44724-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="cam44724-bib-0004" ref-type="bibr"><sup>4</sup></xref>
</p>
              <p>PARP inhibitors (PARPi) catalytically inhibit PARP enzymes and trap PARP on DNA, creating stable PARP‐DNA complexes that interfere with DNA replication and cause cytotoxicity.<xref rid="cam44724-bib-0005" ref-type="bibr"><sup>5</sup></xref> Talazoparib (BMN 673) is one of the most potent and selective PARPi both in terms of catalytic activity and PARP trapping.<xref rid="cam44724-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="cam44724-bib-0007" ref-type="bibr"><sup>7</sup></xref> Talazoparib demonstrated single agent clinical activity with an MTD of 1000mcg daily in small cell lung cancer (SCLC), pancreatic cancer and germline <italic toggle="yes">BRCA1/2</italic> deficient (gBRCA) breast and ovarian cancer in phase I/II trials,<xref rid="cam44724-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="cam44724-bib-0009" ref-type="bibr"><sup>9</sup></xref> and is FDA approved for gBRCA‐mutated advanced breast cancer based on the phase III EMBRACA trial.<xref rid="cam44724-bib-0010" ref-type="bibr"><sup>10</sup></xref> Other PARPi, such as olaparib, niraparib, and rucaparib, are now FDA approved for advanced gBRCA‐mutated breast, pancreatic and prostate cancer, as well as ovarian cancer with and without gBRCA mutations.<xref rid="cam44724-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="cam44724-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="cam44724-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="cam44724-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="cam44724-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="cam44724-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="cam44724-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="cam44724-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="cam44724-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="cam44724-bib-0020" ref-type="bibr"><sup>20</sup></xref>
</p>
              <p>Independent of underlying DNA repair mutations, PARP inhibition sensitizes tumor cells to DNA damage‐inducing cytotoxic agents in vitro,<xref rid="cam44724-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="cam44724-bib-0022" ref-type="bibr"><sup>22</sup></xref> while PARP overexpression has been linked to chemoresistance.<xref rid="cam44724-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="cam44724-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="cam44724-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="cam44724-bib-0026" ref-type="bibr"><sup>26</sup></xref> However, while combinations of cytotoxic chemotherapy and continuously dosed PARPi have been associated with responses in early phase trials, myelosuppressive toxicities have limited tolerability.<xref rid="cam44724-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="cam44724-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="cam44724-bib-0029" ref-type="bibr"><sup>29</sup></xref>, <xref rid="cam44724-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="cam44724-bib-0031" ref-type="bibr"><sup>31</sup></xref> Given the goal of PARP inhibition in this setting to potentiate chemotherapy‐ induced DNA damage, pulsed dose PARP inhibition may preserve antitumor synergy while reducing toxicity.<xref rid="cam44724-bib-0032" ref-type="bibr"><sup>32</sup></xref>, <xref rid="cam44724-bib-0033" ref-type="bibr"><sup>33</sup></xref>, <xref rid="cam44724-bib-0034" ref-type="bibr"><sup>34</sup></xref> Carboplatin is an alkylating agent known to induce PARP activity and is potentiated by PARP inhibition in preclinical models,<xref rid="cam44724-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="cam44724-bib-0035" ref-type="bibr"><sup>35</sup></xref> and the carboplatin/paclitaxel doublet is a well‐tolerated regimen with activity across multiple solid tumor types including ovarian,<xref rid="cam44724-bib-0036" ref-type="bibr"><sup>36</sup></xref> head and neck,<xref rid="cam44724-bib-0037" ref-type="bibr"><sup>37</sup></xref> non‐small cell lung,<xref rid="cam44724-bib-0038" ref-type="bibr"><sup>38</sup></xref> esophageal,<xref rid="cam44724-bib-0039" ref-type="bibr"><sup>39</sup></xref> breast,<xref rid="cam44724-bib-0040" ref-type="bibr"><sup>40</sup></xref> and bladder cancers.<xref rid="cam44724-bib-0037" ref-type="bibr"><sup>37</sup></xref>, <xref rid="cam44724-bib-0041" ref-type="bibr"><sup>41</sup></xref>
</p>
              <p>We hypothesized that the combination of carboplatin and paclitaxel with intermittently dosed talazoparib would improve tolerability of combination therapy, while enhancing antitumor efficacy. Here, we report the safety profile, maximum tolerated dose (MTD), and efficacy of carboplatin and paclitaxel combined with talazoparib on a 3‐ or 7‐day schedule.</p>
            </sec>
            <sec id="cam44724-sec-0006">
              <label>2</label>
              <title>PATIENTS AND METHODS</title>
              <sec id="cam44724-sec-0007">
                <label>2.1</label>
                <title>Eligibility</title>
                <p>Eligible patients had a histologically confirmed advanced solid malignancy and one of the following criteria: (1) reasonable expectation of response to carboplatin and paclitaxel per treating physician (2) deleterious germline <italic toggle="yes">BRCA1/2</italic> mutation or (3) deleterious somatic <italic toggle="yes">BRCA1/2</italic> mutation (see protocol for permitted <italic toggle="yes">BRCA1/2</italic> testing in Appendix <xref rid="cam44724-supitem-0002" ref-type="supplementary-material">S2</xref>). There was no limit on prior lines of therapy. Prior carboplatin was not allowed unless in the neoadjuvant or adjuvant setting ≥6 months prior to enrollment, except in the case of relapsed ovarian cancer, where patients were eligible if ≥6 months since last carboplatin dose. Prior PARPi was permitted. Patients were age ≥ 18 years with an ECOG performance status of ≤2, life expectancy of ≥12 weeks, adequate organ and marrow function and measurable or evaluable disease, as defined by RECIST version 1.1. Patients with peripheral neuropathy &gt;CTCAE grade 1 were excluded, as were patients receiving therapeutic anticoagulation or antiplatelet therapy. Patients with brain metastases were eligible if clinically stable without neurologic symptoms after local therapy for ≥4 weeks and off steroid treatment for ≥2 weeks.</p>
              </sec>
              <sec id="cam44724-sec-0008">
                <label>2.2</label>
                <title>Study design</title>
                <p>This was a multicenter, open‐label phase 1 study. Patients were enrolled at three study sites under an IRB‐approved protocol (NCT02317874). Written informed consent was obtained from all participants prior to enrollment in the trial. The study was conducted in compliance with the Declaration of Helsinki. Patients enrolled in two independent cohorts with separate dosing schedules (Table <xref rid="cam44724-tbl-0001" ref-type="table">1</xref>), with a separate MTD determined for each schedule. For both schedules, carboplatin was administered on Day 1 and paclitaxel on Days 1, 8, 15 of a 21‐day cycle. Paclitaxel was dosed on a weekly rather than every 3 week schedule given equivalent or superior activity of this schedule across phase III studies in ovarian, non‐small cell lung, and breast cancer with more flexibility for dose modification.<xref rid="cam44724-bib-0038" ref-type="bibr"><sup>38</sup></xref>, <xref rid="cam44724-bib-0042" ref-type="bibr"><sup>42</sup></xref>, <xref rid="cam44724-bib-0043" ref-type="bibr"><sup>43</sup></xref>, <xref rid="cam44724-bib-0044" ref-type="bibr"><sup>44</sup></xref>
</p>
                <table-wrap position="float" id="cam44724-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Dose schedules</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="center" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Dose escalation schedule A</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th rowspan="2" align="left" valign="bottom" colspan="1">Dose Level</th>
                        <th style="padding-left:25%" colspan="3" align="center" valign="bottom" rowspan="1">Dose</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th style="padding-left:30%" align="center" valign="bottom" rowspan="1" colspan="1">
                          <p>Carboplatin (AUC) IV</p>
                          <p>Day 1</p>
                        </th>
                        <th style="padding-left:10%" align="left" valign="bottom" rowspan="1" colspan="1">
                          <p>Paclitaxel (mg/m2) IV</p>
                          <p>Days 1, 8, 15</p>
                        </th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">
                          <p>Talazoparib (BMN 673) (mcg) PO once daily</p>
                          <p>Days 1–7</p>
                        </th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Level − 1</td>
                        <td style="padding-left:10%" align="center" valign="top" rowspan="1" colspan="1">5</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">100</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Level 1<sup>a</sup>
</td>
                        <td style="padding-left:10%" align="center" valign="top" rowspan="1" colspan="1">5</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">250</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Level 2</td>
                        <td style="padding-left:10%" align="center" valign="top" rowspan="1" colspan="1">6</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">250</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Level 3</td>
                        <td style="padding-left:10%" align="center" valign="top" rowspan="1" colspan="1">6</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">350</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Level 4</td>
                        <td style="padding-left:10%" align="center" valign="top" rowspan="1" colspan="1">6</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">500</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Level 5</td>
                        <td style="padding-left:10%" align="center" valign="top" rowspan="1" colspan="1">6</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">750</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Level 6</td>
                        <td style="padding-left:10%" align="center" valign="top" rowspan="1" colspan="1">6</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">1000</td>
                      </tr>
                    </tbody>
                  </table>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th colspan="4" align="left" valign="top" rowspan="1">Dose escalation schedule B</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th rowspan="2" align="left" valign="top" colspan="1">Dose level</th>
                        <th colspan="3" align="left" valign="top" rowspan="1">Dose</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <p>Carboplatin (AUC) IV</p>
                          <p>Day 1</p>
                        </th>
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <p>Paclitaxel (mg/m2) IV</p>
                          <p>Days 1, 8, 15</p>
                        </th>
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <p>Talazoparib (BMN 673) (mcg) PO once daily</p>
                          <p>Days 1–3</p>
                        </th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Level 1</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">250</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Level 1<xref rid="cam44724-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">250</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Level 2</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">350</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Level 3</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">500</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Level 4</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">750</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Level 5</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td style="padding-left:20%" align="left" valign="top" rowspan="1" colspan="1">1000</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cam44724-ntgp-0002">
                    <fn id="cam44724-note-0003">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Starting dose level for each schedule.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Pulsed dose schedules in early phase trials of the PARP inhibitors olaparib and veliparib have ranged from 7 to 14 days,<xref rid="cam44724-bib-0032" ref-type="bibr"><sup>32</sup></xref>, <xref rid="cam44724-bib-0034" ref-type="bibr"><sup>34</sup></xref>, <xref rid="cam44724-bib-0045" ref-type="bibr"><sup>45</sup></xref> and given talazoparib's significantly longer mean terminal half‐life (90 ± 58 h),<xref rid="cam44724-bib-0046" ref-type="bibr"><sup>46</sup></xref> talazoparib was dosed daily starting on Day 1 of each cycle prior to carboplatin and paclitaxel, and continued for 7 (schedule A) or 3 days (schedule B). The schedule A dose level 1 was carboplatin AUC 5, paclitaxel 80 mg/m,<xref rid="cam44724-bib-0002" ref-type="bibr"><sup>2</sup></xref> and talazoparib 250 mcg once daily (25% of single agent MTD) (Table <xref rid="cam44724-tbl-0001" ref-type="table">1A</xref>). The schedule B dose level 1 was determined by the schedule A MTD as described below. Talazoparib was supplied by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). Toxicity was evaluated at every cycle for the duration of enrollment for all participants who received at least one dose of study medication. CTCAE v4.0 was used for toxicity grading until March 31, 2018; CTCAE v5.0 was utilized beginning April 1, 2018. Tumor response was assessed with CT or MRI every two cycles (extended to every 6–12 weeks after 4 cycles) by RECIST version 1.1 criteria.<xref rid="cam44724-bib-0047" ref-type="bibr"><sup>47</sup></xref> After 4–6 cycles of combination therapy, patients with clinical benefit, defined as response or stable disease, were allowed to extend therapy as follows at the discretion of the treating provider: (a) continue triplet regimen (b) stop paclitaxel while continuing carboplatin and intermittent talazoparib, (c) stop carboplatin and paclitaxel and transition to continuous talazoparib at single agent MTD of 1000 mcg daily, or d) observation.</p>
              </sec>
              <sec id="cam44724-sec-0009">
                <label>2.3</label>
                <title>Study objectives and statistical methods</title>
                <p>The primary objectives were to determine MTD and RP2D of (1) talazoparib on a 7‐day schedule in combination with carboplatin and paclitaxel, and (2) talazoparib on a 3‐day schedule in combination with carboplatin and paclitaxel, in patients with advanced solid malignancies.</p>
                <p>A standard 3 + 3 design<xref rid="cam44724-bib-0048" ref-type="bibr"><sup>48</sup></xref> was used for dose escalation within each schedule, and after the MTD of each schedule was determined, a dose expansion at that level to a total of 12 patients was planned. Dose escalation was conducted sequentially starting with schedule A, and the starting dose level for schedule B was the MTD from Schedule A (Table <xref rid="cam44724-tbl-0001" ref-type="table">1</xref>). If at any time during the dose expansion period the lower limit of the one‐sided 90% confidence interval for the DLT rate exceeded 20%, accrual to the dose expansion cohort was to be terminated early. If no more than 33% of total patients treated at the MTD in the expanded dose cohort experienced a DLT, this would be the RP2D for each schedule.</p>
                <p>Descriptive summaries of demographics, incidence, and severity of toxicities and disease response are presented. Dose intensity during induction for each agent was defined as percent of full dose for the number of induction cycles received. Talazoparib plasma concentrations were summarized using descriptive statistics.</p>
              </sec>
              <sec id="cam44724-sec-0010">
                <label>2.4</label>
                <title>Definition of <styled-content style="fixed-case" toggle="no">MTD</styled-content> and <styled-content style="fixed-case" toggle="no">DLT</styled-content> and management of toxicities</title>
                <p>The MTD was defined as the highest dose level where &lt;33% of patients experienced a DLT prior to cycle 2. Growth factor support was not permitted in cycle 1, but was permitted in subsequent cycles per the treating physician's discretion. DLTs were defined as: absolute neutrophil count (ANC) &lt; 1000/mcL lasting &gt;7 days, grade 3/4 febrile neutropenia, grade 4 thrombocytopenia lasting &gt;7 days or requiring platelet transfusion, or grade 3/4 thrombocytopenia associated with clinically significant bleeding, grade ≥3 nausea, vomiting, diarrhea, or electrolyte abnormalities lasting &gt;48 h despite maximal medical therapy, grade ≥3 fatigue lasting &gt;7 days despite maximal medical therapy, any other grade ≥3 non‐hematologic toxicity, or delay in starting cycle 2 by ≥2 weeks due to toxicity. Patients must have completed at least day 1 through day 8 of planned cycle 1 treatment to be considered evaluable, unless a DLT occurred in this timeframe, in which case they would be considered evaluable and classified as a DLT regardless of whether day 8 treatment was completed. Patients who did not complete cycle 1 for reasons other than safety (e.g., withdrawal of consent, noncompliance, disease progression) OR experienced a ≥ 7‐day treatment delay within Cycle 1 for reasons other than safety, were also deemed inevaluable. Dose modification was required for grade 3/4 ANC lasting &gt;7 days or with fever, grade 4 thrombocytopenia &gt;7 days or requiring platelet transfusion. Dose modifications of paclitaxel were required for intolerable grade 2 or ≥ grade 3 peripheral neuropathy. Up to two dose reductions were allowed.</p>
              </sec>
              <sec id="cam44724-sec-0011">
                <label>2.5</label>
                <title>Pharmacokinetic and pharmacodynamic methods</title>
                <p>For pharmacokinetic (PK) analyses, plasma samples were collected before and approximately 4 h after talazoparib administration on C1D1, C1D7 (schedule A), or C1D3 (schedule B), C2D1, and D1 of cycles 3–5 for cycles coinciding with radiographic assessment. On each day when pharmacodynamic (PD) or plasma samples were collected, talazoparib was dosed in clinic (prior to paclitaxel and carboplatin administration). Plasma concentrations of talazoparib were evaluated by a validated LC/MS assay. For PD analyses, whole blood samples were obtained before and approximately 4 h after talazoparib administration on C1D1, C1D3 (schedule B), or C1D7 (schedule A), and C2D1, for assessment of PAR inhibition and DNA damage response pathway activation (γH2AX, RAD51 foci) in peripheral blood mononuclear cells (PBMCs) (see Data <xref rid="cam44724-supitem-0001" ref-type="supplementary-material">S1</xref>).</p>
              </sec>
              <sec id="cam44724-sec-0012">
                <label>2.6</label>
                <title>Exploratory analysis of germline/somatic mutation status</title>
                <p>Standard of care germline genetic testing was available for 30/43 patients and archival tumor tissue (available for 18/43 patients) was submitted for somatic next‐generation sequencing (NGS) with the Foundation One NGS panel. The following genes were included in the analysis: <italic toggle="yes">ARID1A, ATM, ATRX, BARD1, BLM, BRCA1, BRCA2, BRIP1 (FANCJ), CDK12, CHEK1, CHEK2, FANCA, FANCD2, FANCE, FANCF, FANCL, FANCM, MRE11, MSH2, MSH6, NBN, PALB2, PPP2R2A, RAD50, RAD51B, RAD51C, RAD51D, RAD54L, WRN</italic>, and <italic toggle="yes">XRCC3</italic>. When feasible, the NGS results were sent to the patient's treating physician for referral to genetic counseling if indicated.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="cam44724-sec-0013">
              <label>3</label>
              <title>RESULTS</title>
              <sec id="cam44724-sec-0014">
                <label>3.1</label>
                <title>Demographics and enrollment</title>
                <p>Forty‐three patients enrolled between August of 2015 and July of 2019 (Table <xref rid="cam44724-tbl-0002" ref-type="table">2</xref>), with the most common tumor types being breast (25.6%) and gastrointestinal/hepatobiliary (25.6%) cancers. The majority had received prior chemotherapy (34.8% 1 regimen, 32.5% &gt;2 regimens), 39.5% had germline <italic toggle="yes">BRCA1/2</italic> mutations, and 11.6% had received prior PARP inhibitor. Patients in both schedules received a median of four cycles of induction therapy with carboplatin, paclitaxel, and talazoparib (range 1–9), and 37.2% went on to receive one of the protocol‐approved maintenance therapy regimens (Table <xref rid="cam44724-tbl-0003" ref-type="table">3</xref>). Six patients (13.9%) received carboplatin plus talazoparib maintenance for median of two cycles (range 2–8), while 13 patients (30.2%) received talazoparib dosed continuously for a median of eight cycles (range 1–63). Of note, four patients who initially received carboplatin plus talazoparib maintenance were subsequently transitioned to talazoparib monotherapy (Table <xref rid="cam44724-tbl-0003" ref-type="table">3</xref>). Median duration of follow‐up on study was 4.3 months (range 0.6–56.6), and two patients remained on maintenance talazoparib at the end of the study.</p>
                <table-wrap position="float" id="cam44724-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Patient demographics</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="center" span="1"/>
                    <col align="center" span="1"/>
                    <col align="center" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">No. of Patients (%)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">All</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Schedule A</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Schedule B</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">N</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">43</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">23</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">20</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Age, years</td>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">56</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">55</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">56</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Range</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">37–76</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">37–70</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">43–76</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Gender</td>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Male</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">21 (48.8)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">9 (39.1)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">12 (60)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Female</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">22 (51.1)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">14 (60.8)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">8 (40)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ECOG PS</td>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">17 (39.5)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">10 (43.4)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">7 (35)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">24 (55.8)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">11 (47.8)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">13 (65)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">2 (4.6)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">2 (8.7)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Primary cancer</td>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Breast</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">11 (25.6)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">9 (39.1)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">2 (10)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pancreas</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">7 (16.3)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">3 (13)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">4 (20)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Colorectal</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">4 (9.3)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">4 (20)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Non‐melanoma skin</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">3 (6.9)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">3 (13)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Non‐small cell lung</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">3 (6.9)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">3 (15)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Ovarian</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">3 (6.9)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">3 (13)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other<xref rid="cam44724-note-0004" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">12 (27.9)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">5 (21.7)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">7 (35)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Prior lines of cytotoxic therapy</td>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">14 (32.5)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">9 (39.1)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">5 (25)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">15 (34.8)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">9 (39.1)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">6 (30)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">≥2</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">14 (32.5)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">5 (21.7)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">9 (45)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Prior PARP inhibitor</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">5 (11.6)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">2 (8.7)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">3 (15)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Germline BRCA mutation status</td>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                        <td align="center" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">gBRCA1mut</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">7 (16.3)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">5 (21.7)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">2 (10)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">gBRCA2mut</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">10 (23.2)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">7 (30.4)</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">3 (15)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cam44724-ntgp-0003">
                    <fn id="cam44724-note-0004">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Includes prostate (2), urothelial (2), adenoid cystic carcinoma (2), head and neck squamous cell carcinoma (1), melanoma (1), uterine leiomyosarcoma (1), and one patient each with duodenal, esophageal, and gallbladder carcinoma.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap position="float" id="cam44724-tbl-0003" content-type="TABLE">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Treatment</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">All</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Schedule A</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Schedule B</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Induction cycles</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Range</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1–9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1–8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1–9</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Maintenance cycles</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">No of patients (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">16 (37.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12 (52.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4 (20)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Talazoparib/carboplatin</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">No of patients (%)<xref rid="cam44724-note-0005" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6 (13.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4 (17.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (10)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Median cycles</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Range</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2–9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2–9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2–2</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Talazoparib monotherapy</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">No of patients (%)<xref rid="cam44724-note-0005" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13 (30.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9 (39.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (10)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Median cycles</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Range</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1–63</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1–63</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2–18</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <p>Dose modification at MTD</p>
                          <p>(No of patients, %)</p>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Ever</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27 (96.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14 (93)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13 (100)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">During induction</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27 (96.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14 (93)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13 (100)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Chemotherapy dose reduction</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27 (96.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14 (93)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13 (100)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">BMN dose reduction</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (3.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Induction % dose intensity at MTD (mean, SD)<xref rid="cam44724-note-0006" ref-type="table-fn"><sup>b</sup></xref>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Carboplatin</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">91 (9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">93 (7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">89 (10)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Paclitaxel</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">68 (17)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">69 (18)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">68 (17)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">BMN</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">92 (20)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">89 (24)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">94 (14)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <p>Supportive care</p>
                          <p>(No of patients, %)</p>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Growth factor</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15 (34.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11 (47.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4 (20)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Any transfusion</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14 (32.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6 (26.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8 (40)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">pRBC transfusion</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12 (27.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6 (26.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6 (30)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Platelet transfusion</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (4.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (10)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Reason for treatment discontinuation (No of patients, %)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Disease progression</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">26 (60.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14 (60.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12 (60)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Adverse event</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5 (11.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (13)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (10</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Intercurrent illness</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (6.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (4.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (10)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Death on study</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (2.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (5)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Study completion/transition to commercial drug</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (4.66)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (8.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6 (13.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (13)<xref rid="cam44724-note-0007" ref-type="table-fn"><sup>c</sup></xref>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (15)<xref rid="cam44724-note-0008" ref-type="table-fn"><sup>d</sup></xref>
</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cam44724-ntgp-0004">
                    <fn id="cam44724-note-0005">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Patients who received both talazoparib/carboplatin and subsequent talazoparib monotherapy maintenance are reported in both groups.</p>
                    </fn>
                    <fn id="cam44724-note-0006">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Percent of full dose based on number of induction cycles.</p>
                    </fn>
                    <fn id="cam44724-note-0007">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Schedule A (one patient each): Physician's decision, Patient not tolerating therapy, and Switched to alternative treatment.</p>
                    </fn>
                    <fn id="cam44724-note-0008">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>Schedule B (one patient each): Refused further treatment, late determination of eligibility, and treatment held for more than 3 weeks.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="cam44724-sec-0015">
                <label>3.2</label>
                <title>Toxicity</title>
                <p>In the schedule A dose escalation, 0/3 patients at dose level 1, 0/3 patients at dose level 2, and 2/3 patients at dose level 3 experienced DLTs (Table <xref rid="cam44724-tbl-0004" ref-type="table">4</xref>). Thus, the MTD for schedule A was determined to be dose level 2 (carboplatin AUC 6, paclitaxel 80 mg/m,<xref rid="cam44724-bib-0002" ref-type="bibr"><sup>2</sup></xref> talazoparib 250 mcg day 1–7). In the schedule A MTD expansion cohort, 2/9 additional evaluable patients experienced DLTs, remaining below the 33% threshold at the MTD, and confirming dose level 2 as the MTD for schedule A. The reported DLTs in schedule A were grade 3 and 4 neutropenia and grade 4 febrile neutropenia (Table <xref rid="cam44724-tbl-0004" ref-type="table">4</xref>). Five out of 23 patients were unevaluable for DLT due to omission of cycle 1 day 8 paclitaxel without meeting protocol‐defined DLT toxicity criteria. In the dose level 1 escalation cohort, this included one patient with grade 3 nausea in the setting of suboptimal antiemetic support, one patient who was hospitalized with a urinary tract infection without fever or neutropenia deemed unrelated to study treatment, and one patient with grade 2 total bilirubin elevation ultimately identified as Gilbert's disease. In the dose level 2 escalation cohort this included one patient with grade 3 abdominal pain and one patient hospitalized with a venous thromboembolic event, both deemed to be attributable to disease progression by treating investigators and PI.</p>
                <table-wrap position="float" id="cam44724-tbl-0004" content-type="TABLE">
                  <label>TABLE 4</label>
                  <caption>
                    <p>Dose levels and dose limiting toxicities (DLTs)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Dose level</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Talazoparib</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Carboplatin (AUC)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Paclitaxel (mg/m2)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Enrolled (N)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Evaluable (N)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"># Patients with DLTs</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">DLTs</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">A/Level 1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">250mcg D1‐7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">A/Level 2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">250mcg D1‐7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2<xref rid="cam44724-note-0009" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <p>Pt 1: G3 neutropenia</p>
                          <p>Pt 2: G4 neutropenia</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">A/Level 3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">350mcg D1‐7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <p>Pt 1: G3 febrile neutropenia</p>
                          <p>Pt 2: G3 neutropenia</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">B/Level 1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">250mcg D1‐3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3<xref rid="cam44724-note-0009" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <p>Pt 1: G3 neutropenia</p>
                          <p>Pt 2: G3 neutropenia</p>
                          <p>Pt 3: G3 neutropenia</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">B/Level 2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">350mcg D1‐3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">80</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <p>Pt 1: G3 febrile neutropenia, G4 neutropenia, G4 thrombocytopenia</p>
                          <p>Pt 2: G4 neutropenia</p>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cam44724-ntgp-0005">
                    <fn id="cam44724-note-0009">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>DLTs occurred in the dose expansion cohort.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>In the schedule B dose escalation, 0/3 patients experienced DLTs at dose level 1, however 2/6 experienced DLTs at dose level 2, exceeding the MTD (Table <xref rid="cam44724-tbl-0004" ref-type="table">4</xref>), with subsequent dose expansion at dose level 1. In the overall schedule B dose level 1 (MTD) cohort comprising both escalation and expansion cohorts, 3/11 evaluable patients experienced DLTs. Since the prespecified 33% or less threshold to confirm the MTD would still have been met if a 12th evaluable patient were to enroll and experience a DLT, enrollment in this schedule was not re‐opened. Thus, the confirmed MTD was dose level 1 (carboplatin AUC 6, paclitaxel 80 mg/m,<xref rid="cam44724-bib-0002" ref-type="bibr"><sup>2</sup></xref> talazoparib 250 mcg day 1–3). All three DLTs at dose level 1 (MTD) were grade 3 neutropenia, while the DLTs at dose level 2 included grade 3 febrile neutropenia, grade 4 neutropenia and grade 4 thrombocytopenia (Table <xref rid="cam44724-tbl-0004" ref-type="table">4</xref>). Three out of 20 patients in schedule B were unevaluable for DLT. This included one patient in the dose level 1 expansion cohort who missed the third dose of talazoparib due to administrative error, and one patient in the dose level 1 escalation cohort for whom timing of follow‐up CBC was not within the window to determine duration of neutropenia. One additional patient in the dose level 1 escalation cohort did not receive study therapy due to determination of ineligibility post‐registration so was not included in DLT, toxicity and efficacy analyses.</p>
                <p>Common AEs of any grade experienced by at least 10% of participants and at least possibly related to the study medications are summarized in Table <xref rid="cam44724-tbl-0005" ref-type="table">5</xref>. Myelosuppression was the most common toxicity, and over half of the participants experienced a grade 3/4 hematologic toxicity, but febrile neutropenia was uncommon (Table <xref rid="cam44724-tbl-0005" ref-type="table">5</xref>). Fatigue, nausea, and diarrhea were also common but primarily grade 1/2. Peripheral neuropathy was common, but mild in nature. Growth factor support was administered to 35% of patients after cycle 1, in the form of non‐PEGylated G‐CSF on an intermittent weekly schedule, and 32% of patients required at least one transfusion (Table <xref rid="cam44724-tbl-0003" ref-type="table">3</xref>), primarily during the induction phase of treatment (Table <xref rid="cam44724-supitem-0001" ref-type="supplementary-material">S1</xref>). Dose delay/modification occurred in 86.6% and 100% of patients treated at the MTD for schedules A and B, respectively, however mean dose intensity during the induction phase was 91% for carboplatin, 68% for paclitaxel, and 92% for talazoparib, and the rate of treatment discontinuation due to adverse events was low, occurring in only three patients (13%) in schedules A and two (10%) in B (Table <xref rid="cam44724-tbl-0003" ref-type="table">3</xref>). One patient developed myelodysplastic syndrome (MDS) while on maintenance talazoparib, 16 months after starting induction therapy. While MDS is a rare (0.3%) complication of talazoparib therapy,<xref rid="cam44724-bib-0046" ref-type="bibr"><sup>46</sup></xref> the patient had prior exposure to alkylating agents including temozolomide 4 years prior and cisplatin 2 years prior to the MDS diagnosis, which was investigator attributed as more likely related to these prior therapies. One patient experienced a grade 5 intracranial hemorrhage associated with persistent grade 3 thrombocytopenia in the setting of extensive malignant bone marrow involvement. Non‐contrast CT was concerning for brain metastases, but it was decided to attribute patient's death as at least possibly related to study therapy.</p>
                <table-wrap position="float" id="cam44724-tbl-0005" content-type="TABLE">
                  <label>TABLE 5</label>
                  <caption>
                    <p>Toxicities at least possibly related to treatment. Number of patients (%); n = 42<xref rid="cam44724-note-0010" ref-type="table-fn"><sup>a</sup></xref>
</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Event</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Any grade</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Grade 1</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Grade 2</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Grade 3</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Grade 4</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Any adverse event</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">42 (100)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">41 (98)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">39 (93)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">41 (98)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14 (33)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Neutrophil count decreased</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">38 (90)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14 (33)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">29 (69)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">27 (64)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">13 (31)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Anemia</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">38 (90)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">16 (38)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">34 (81)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">22 (52)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Platelet count decreased</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">33 (79)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">25 (60)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">27 (64)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10 (24)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5 (12)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Fatigue</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">29 (69)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">25 (60)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">12 (29)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6 (14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Nausea</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">22 (52)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">19 (45)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7 (17)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Diarrhea</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">19 (45)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15 (36)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Lymphocyte count decreased</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">17 (40)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">12 (29)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">12 (29)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">9 (21)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Peripheral neuropathy</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">12 (29)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">12 (29)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Vomiting</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">11 (26)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">8 (19)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Alopecia</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">11 (26)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6 (14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5 (12)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Anorexia</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10 (24)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">8 (19)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Constipation</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">9 (21)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">8 (19)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Hypophosphatemia</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">8 (19)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6 (14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Mucositis</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">8 (19)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7 (17)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Myalgias</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7 (17)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6 (14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Abdominal pain</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6 (14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Hypomagnesemia</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6 (14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Dizziness</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6 (14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6 (14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Rash</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6 (14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6 (14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Hypertension</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5 (12)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ALT increased</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5 (12)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Dysgeusia</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5 (12)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Dyspepsia</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5 (12)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Headache</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5 (12)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5 (12)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Alkaline phosphatase increased</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Dyspnea</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Weight loss</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Dehydration</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Hypoalbuminemia</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Sinus tachycardia</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (10)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cam44724-ntgp-0006">
                    <fn id="cam44724-note-0010">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>One patient in schedule B who did not receive any study medication due to determination of ineligibility post‐registration is not included in this analysis.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="cam44724-sec-0016">
                <label>3.3</label>
                <title>Clinical efficacy</title>
                <p>Among the 38 patients evaluable for disease response, there were 3/38 complete (CR) and 12/38 partial (PR) responses. All three patients with CRs were enrolled in schedule A. An additional 17 patients across both cohorts had stable disease (SD) (Table <xref rid="cam44724-tbl-0006" ref-type="table">6</xref>). Among patients with prior PARP inhibitor exposure, 1/5 had a PR, 3/5 had SD, and 1/5 had progressive disease as best response.</p>
                <table-wrap position="float" id="cam44724-tbl-0006" content-type="TABLE">
                  <label>TABLE 6</label>
                  <caption>
                    <p>Efficacy</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1"/>
                        <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Number of patients (%)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">All</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Schedule A</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Schedule B</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Best response</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CR</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3/38 (7.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3/22 (13.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0/16 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PR</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12/38 (31.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7/22 (31.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5/16 (31.2)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SD</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17/38 (44.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9/22 (40.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8/16 (50)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PD</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6/38 (15.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3/22 (13.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3/16 (18.7)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Clinical benefit (CR, PR, or SD)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">32/38 (84.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19/22 (86.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13/16 (81.2)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Best response, prior PARPi</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CR</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0/5 (0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PR</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1/5 (20)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SD</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3/5 (60)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PD</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1/5 (20)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Clinical benefit (CR, PR, or SD)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4/5 (80)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td colspan="4" align="left" valign="top" rowspan="1">Patients receiving ≥6 cycles of maintenance therapy</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Total</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12/38 (31.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10/22 (45.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2/16 (12.5)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Duration of maintenance (months)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Median</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12.86</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Range</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5.5–55.5+</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Tumor type</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Breast</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Ovarian</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Cutaneous SCC</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Adenoid cystic carcinoma</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Uterine leiomyosarcoma</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Urothelial</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
                <p>Twelve patients received at least six cycles of talazoparib maintenance therapy (with or without carboplatin) after completing at least four cycles of initial triplet therapy. In this group, the median duration of maintenance therapy was 12.9 months, with a range from 5.5 to 55.5+ months (Table <xref rid="cam44724-tbl-0006" ref-type="table">6</xref>); two patients remained on maintenance talazoparib at time of study completion. These patients represented a range of tumor types with the most common being breast, ovarian, and cutaneous squamous cell carcinoma (Table <xref rid="cam44724-tbl-0006" ref-type="table">6</xref>).</p>
              </sec>
              <sec id="cam44724-sec-0017">
                <label>3.4</label>
                <title>PK/PD</title>
                <p>The mean plasma concentrations of talazoparib 4 h after the first dose of cycle 1 were 0.612 ng/ml (44.1 CV%) and 0.58 ng/ml (44.9 CV%) for schedule A and B, respectively. For Schedule A, the mean talazoparib plasma concentration on C1D7 4 h post‐dose was 2.95 ng/ml (44.8 CV%). For Schedule B, the mean talazoparib plasma concentration was 2.19 (55.7 CV%). Plasma concentrations 4 h following the first dose of cycles 2 and 3 were similar for both schedules.</p>
                <p>Pharmacodynamic analyses in schedule A demonstrated no significant change in markers of DNA damage response (Rad51 foci and γH2AX intensity) or PARP inhibition (PAR intensity) in peripheral blood mononuclear cells (PBMCs) from baseline to C1D7 or C2D1 (Figure <xref rid="cam44724-supitem-0001" ref-type="supplementary-material">S1</xref>) and as such no pharmacodynamic analysis of schedule B was undertaken.</p>
              </sec>
              <sec id="cam44724-sec-0018">
                <label>3.5</label>
                <title>Germline/somatic <styled-content style="fixed-case" toggle="no">DNA</styled-content> damage response pathway alterations</title>
                <p>An exploratory analysis of DNA damage response (DDR) pathway mutation status was conducted for patients with standard of care germline testing (30/43 patients) and/or sufficient archival tumor tissue for Foundation One NGS panel sequencing (18/43 patients), which does not distinguish between germline and somatic mutations (Figure <xref rid="cam44724-supitem-0001" ref-type="supplementary-material">S2</xref>). Seven patients had <italic toggle="yes">gBRCA1</italic> and 10 patients had <italic toggle="yes">gBRCA2</italic> mutations. Two patients had germline mutations in other DNA damage response (DDR) pathway genes (<italic toggle="yes">ATM</italic> and <italic toggle="yes">ARID1A</italic>), and five patients had deleterious mutations in DDR pathway genes (<italic toggle="yes">PALB2, FANCA, ARID1A, BRIP1</italic>, and <italic toggle="yes">MSH6</italic>) identified on Foundation One NGS. Two out of 3 complete responses and 8/10 partial responses occurred in patients with DDR pathway alterations (Figure <xref rid="cam44724-supitem-0001" ref-type="supplementary-material">S2</xref>). Six out of 12 patients who received ≥6 cycles of maintenance therapy had <italic toggle="yes">BRCA1/2</italic> alterations on germline testing, while two additional patients in this group had DDR pathway alterations detected on Foundation One NGS, including a patient with cutaneous squamous cell cancer and a pathogenic <italic toggle="yes">PALB2</italic> mutation and a patient with breast cancer and a pathogenic <italic toggle="yes">FANCA</italic> mutation.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="cam44724-sec-0019">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>This phase I study identified a recommended phase 2 dose of carboplatin AUC 6, paclitaxel 80 mg/m<sup>2</sup>, and talazoparib 250 mcg for both the 3‐day and 7‐day schedule. However, this regimen was associated with significant myelosuppression during the induction phase, with a third of patients receiving growth factor after cycle 1, and a third requiring transfusion support. Dose modifications were also frequently required, most commonly omitting one weekly paclitaxel dose. Unexpectedly, there was no evidence of improved tolerability for the 3‐day versus 7‐day schedule. However, the rate of febrile neutropenia was low, and supportive care allowed patients to complete induction chemotherapy with relatively preserved chemotherapy intensity and few discontinuations due to toxicity, similar to what has been reported in other studies evaluating PARPi with chemotherapy.<xref rid="cam44724-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="cam44724-bib-0045" ref-type="bibr"><sup>45</sup></xref> Pharmacokinetic analyses revealed no differences in plasma concentration of talazoparib between schedules.</p>
              <p>Germline <italic toggle="yes">BRCA1/2</italic> mutations are well‐established predictive biomarkers of PARPi sensitivity,<xref rid="cam44724-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="cam44724-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="cam44724-bib-0049" ref-type="bibr"><sup>49</sup></xref> and predict sensitivity to PARPi monotherapy in metastatic breast<xref rid="cam44724-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="cam44724-bib-0050" ref-type="bibr"><sup>50</sup></xref> and ovarian<xref rid="cam44724-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="cam44724-bib-0051" ref-type="bibr"><sup>51</sup></xref>, <xref rid="cam44724-bib-0052" ref-type="bibr"><sup>52</sup></xref> cancer, and to PARPi maintenance therapy in metastatic ovarian<xref rid="cam44724-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="cam44724-bib-0018" ref-type="bibr"><sup>18</sup></xref> and pancreatic<xref rid="cam44724-bib-0014" ref-type="bibr"><sup>14</sup></xref> cancer. Subsequent trials have identified additional somatic or germline alterations in DNA damage repair (DDR) pathway genes associated with PARPi sensitivity<xref rid="cam44724-bib-0053" ref-type="bibr"><sup>53</sup></xref> including germline <italic toggle="yes">PALB2</italic> mutations and somatic <italic toggle="yes">BRCA1/2</italic> mutations in metastatic breast cancer<xref rid="cam44724-bib-0054" ref-type="bibr"><sup>54</sup></xref> and germline or somatic <italic toggle="yes">BRCA1/2</italic> and <italic toggle="yes">ATM</italic> alterations in metastatic castrate resistant prostate cancer<xref rid="cam44724-bib-0013" ref-type="bibr"><sup>13</sup></xref>’.<xref rid="cam44724-bib-0055" ref-type="bibr"><sup>55</sup></xref> In the GOG‐3005 study investigating veliparib in combination with chemotherapy, the benefit of the PARP inhibitor was also extended to all patients with newly diagnosed ovarian cancer.<xref rid="cam44724-bib-0056" ref-type="bibr"><sup>56</sup></xref>
</p>
              <p>The majority of patients on this study with objective responses did have DDR pathway genomic alterations (Figure <xref rid="cam44724-supitem-0001" ref-type="supplementary-material">S2</xref>). However, the subset of 12 patients who received at least six cycles of maintenance therapy after induction included five patients with solid tumors in which PARP inhibition has been less well studied, including two with cutaneous squamous cell carcinoma, one of whom had a somatic pathogenic PALB2 alteration. This supports our clinical observations, which suggest further consideration of development of PARPi in other solid tumor types beyond breast and ovarian cancer, particularly those with DDR alterations.</p>
              <p>The phase III BROCADE3 trial found that the addition of intermittent veliparib to carboplatin plus paclitaxel in advanced gBRCA‐mutated breast cancer with 0–2 prior lines of therapy improved PFS and duration of response,<xref rid="cam44724-bib-0057" ref-type="bibr"><sup>57</sup></xref> but in contrast to the induction‐maintenance strategy utilized in our study, patients in BROCADE received a median of 10 cycles of cytotoxic chemotherapy, with only 41% of patients in the veliparib arm and 34% of patients in the placebo arm transitioning to blinded veliparib/placebo monotherapy prior to progression. Our data suggest that patients who complete 4–6 cycles of induction combination therapy without disease progression may be able to transition to maintenance monotherapy, which also draws support from the maintenance PARPi post‐platinum induction approach in advanced pancreatic<xref rid="cam44724-bib-0014" ref-type="bibr"><sup>14</sup></xref> and ovarian<xref rid="cam44724-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="cam44724-bib-0018" ref-type="bibr"><sup>18</sup></xref> cancer. Furthermore, we observed responses with this strategy in tumor types beyond breast and ovarian cancer in our cohort, suggesting that it may have value across HRD‐deficient tumors.</p>
              <p>Overall, the induction‐maintenance design in our study did facilitate a shorter duration of cytotoxic chemotherapy in the advanced disease setting, at the expense of significant toxicity during the induction phase in both schedules. The exploratory analysis of somatic and germline DDR mutation status, available for the majority of enrolled patients, did demonstrate disease responses in patients with DDR alterations in tumor types such as head and neck squamous cell cancer in which the impact on DDR mutation status on PARPi/platinum sensitivity is less well characterized. Limitations include the finding that the MTD for talazoparib was significantly lower for both the 3‐ and 7‐day schedules compared to monotherapy PARPi studies. However, while maximal PARP inhibition is seen with doses ≥600mcg in the monotherapy setting, pharmacodynamic studies demonstrated significant inhibition at doses as low as 200 mcg, suggesting that the MTD here would be expected to result in significant target engagement.<xref rid="cam44724-bib-0008" ref-type="bibr"><sup>8</sup></xref>
</p>
              <p>In conclusion, the combination of talazoparib with carboplatin and paclitaxel is feasible with an intermittent, lower dose schedule of talazoparib and appropriate supportive care. However, modification of the cytotoxic chemotherapy component of the regimen would be a consideration in further development, given the challenging toxicity profile. Future studies of PARPi combined with single agent platinum or other DNA damaging chemotherapy may maximize the effect of DNA damage with a more favorable toxicity profile, potentially expanding use of PARPi to other solid tumors. Patient selection for PARPi based on genomic alterations affecting DNA repair should continue to be explored in future trials.</p>
            </sec>
            <sec sec-type="COI-statement" id="cam44724-sec-0021">
              <title>CONFLICT OF INTEREST</title>
              <p>Ticiana A. Leal: Consulting ‐ Boehringer‐Ingelheim, Jazz Pharmaceuticals, Genentech, Lilly; Advisory Boards ‐ AstraZeneca, EMD Serono, Merck, Boehringer‐Ingelheim, Blueprint, Bayer, Janssen, Mirati. Lisa M. Barroilhet: Advisory boards ‐ Clovis, Astrazeneca, Kiayatec. Kari B. Wisinski: Research support ‐ Pfizer, Context, Novartis; Scientific Advisory boards ‐ Eisai, AstraZeneca, Pfizer, Sanofi, Daiichi Sankyo, Novartis. The other authors declare no potential conflict of interest.</p>
            </sec>
            <sec id="cam44724-sec-0022">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p>Ticiana A. Leal: Conceptualization, resources, funding acquisition, investigation, methodology, supervision, writing‐original draft, writing‐review, and editing. Marina N. Sharifi: Data curation, formal analysis, investigation, visualization, methodology, writing‐original draft, writing‐review, and editing. Nancy Chan: Conceptualization, resources, methodology, writing‐review, and editing. Robert Wesolowski: Conceptualization, resources, methodology, writing‐review, and editing. Anita A. Turk: Data curation, formal analysis, visualization, methodology, writing‐review, and editing. Justine Y. Bruce: Resources, writing‐review, and editing. Ruth M. O'Regan: Resources, writing‐review, and editing. Jens Eickhoff: Resources, methodology, writing‐review, and editing. Lisa M. Barroilhet: Resources, writing‐review, and editing. Jyoti Malhotra: Conceptualization, resources, methodology, writing‐review, and editing. Janice Mehnert: Resources, writing‐review, and editing. Eugenia Girda: Resources, writing‐review, and editing. Elizabeth Wiley: Resources and investigation. Natalie Schmitz: Resources, formal analysis, investigation, visualization, methodology, writing‐review, and editing. Shannon Andrews: Resources, formal analysis, investigation, and methodology. Glenn Liu: Conceptualization, resources, methodology, writing‐review, and editing. Kari B. Wisinski: Conceptualization, resources, supervision, funding acquisition, methodology, writing‐original draft, writing‐review, and editing.</p>
            </sec>
            <sec id="cam44724-sec-0023">
              <title>ETHICS STATEMENT</title>
              <p>This study was conducted under an IRB‐approved protocol (NCT02317874). Written informed consent was obtained from all participants prior to enrollment in the trial. The study was conducted in compliance with the Declaration of Helsinki.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="cam44724-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p>
Appendix S1
</p>
                </caption>
                <media xlink:href="CAM4-11-3969-s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cam44724-supitem-0002" position="float" content-type="local-data">
                <caption>
                  <p>
Appendix S2
</p>
                </caption>
                <media xlink:href="CAM4-11-3969-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="cam44724-sec-0020">
              <title>ACKNOWLEDGMENTS</title>
              <p>The authors thank the UW Carbone Cancer Center Cancer Therapy Discovery and Development Program (CTD2) for essential administrative and logistical support. The authors thank Cameron Scarlett, Ph.D. and Molly Pellitteri Hahn, M.S. (Analytical Instrumentation Center; School of Pharmacy; University of Wisconsin, Madison, WI) for their expertise in analyzing plasma samples for talazoparib concentration on the facility's Sciex 5500. The authors also thank Shannon Andrews, Ph.D. (Cancer Pharmacology Lab, University of Wisconsin Carbone Cancer Center) for the biomarker analysis of PAR, γH2AX, and RAD51. The biomarker analysis was completed under the expertise of Jennifer Schehr, Ph.D., Anupama Singh, Ph.D. (UWCCC Circulating Biomarker Core), and Lauren Nettenstrom, M.S. (UWCCC Flow Lab). We thank Sara Matthiesen, B.S. (Cancer Pharmacology Lab Sample Acquisition Services) for Biospecimen management.</p>
            </ack>
            <sec sec-type="data-availability" id="cam44724-sec-0025">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>Data available on request due to privacy/ethical restrictions</p>
            </sec>
            <ref-list content-type="cited-references" id="cam44724-bibl-0001">
              <title>REFERENCES</title>
              <ref id="cam44724-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0001"><string-name><surname>Eisemann</surname><given-names>T</given-names></string-name>, <string-name><surname>Pascal</surname><given-names>JM</given-names></string-name>. <article-title>Poly(ADP‐ribose) polymerase enzymes and the maintenance of genome integrity</article-title>. <source>Cell Mol Life Sci</source>. <year>2020</year>;<volume>77</volume>(<issue>1</issue>):<fpage>19</fpage>‐<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00018-019-03366-0</pub-id>
<pub-id pub-id-type="pmid">31754726</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0002"><string-name><surname>Ray Chaudhuri</surname><given-names>A</given-names></string-name>, <string-name><surname>Nussenzweig</surname><given-names>A</given-names></string-name>. <article-title>The multifaceted roles of PARP1 in DNA repair and chromatin remodelling</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2017</year>;<volume>18</volume>(<issue>10</issue>):<fpage>610</fpage>‐<lpage>621</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrm.2017.53</pub-id>
<pub-id pub-id-type="pmid">28676700</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0003"><string-name><surname>Farmer</surname><given-names>H</given-names></string-name>, <string-name><surname>McCabe</surname><given-names>N</given-names></string-name>, <string-name><surname>Lord</surname><given-names>CJ</given-names></string-name>, et al. <article-title>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</article-title>. <source>Nature</source>. <year>2005</year>;<volume>434</volume>(<issue>7035</issue>):<fpage>917</fpage>‐<lpage>921</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature03445</pub-id>
<pub-id pub-id-type="pmid">15829967</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0004"><string-name><surname>Bryant</surname><given-names>HE</given-names></string-name>, <string-name><surname>Schultz</surname><given-names>N</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>HD</given-names></string-name>, et al. <article-title>Specific killing of BRCA2‐deficient tumours with inhibitors of poly(ADP‐ribose) polymerase</article-title>. <source>Nature</source>. <year>2005</year>;<volume>434</volume>(<issue>7035</issue>):<fpage>913</fpage>‐<lpage>917</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature03443</pub-id>
<pub-id pub-id-type="pmid">15829966</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0005"><string-name><surname>Murai</surname><given-names>J</given-names></string-name>, <string-name><surname>Huang</surname><given-names>SY</given-names></string-name>, <string-name><surname>Renaud</surname><given-names>A</given-names></string-name>, et al. <article-title>Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib</article-title>. <source>Mol Cancer Ther</source>. <year>2014</year>;<volume>13</volume>(<issue>2</issue>):<fpage>433</fpage>‐<lpage>443</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0803</pub-id>
<pub-id pub-id-type="pmid">24356813</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0006"><string-name><surname>Turk</surname><given-names>AA</given-names></string-name>, <string-name><surname>Wisinski</surname><given-names>KB</given-names></string-name>. <article-title>PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside</article-title>. <source>Cancer</source>. <year>2018</year>;<volume>124</volume>(<issue>12</issue>):<fpage>2498</fpage>‐<lpage>2506</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.31307</pub-id>
<pub-id pub-id-type="pmid">29660759</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0007"><string-name><surname>Shen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Rehman</surname><given-names>FL</given-names></string-name>, <string-name><surname>Feng</surname><given-names>Y</given-names></string-name>, et al. <article-title>BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency</article-title>. <source>Clin Cancer Res</source>. <year>2013</year>;<volume>19</volume>(<issue>18</issue>):<fpage>5003</fpage>‐<lpage>5015</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-1391</pub-id>
<pub-id pub-id-type="pmid">23881923</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0008"><string-name><surname>de Bono</surname><given-names>J</given-names></string-name>, <string-name><surname>Ramanathan</surname><given-names>RK</given-names></string-name>, <string-name><surname>Mina</surname><given-names>L</given-names></string-name>, et al. <article-title>Phase I, Dose‐Escalation, Two‐Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers</article-title>. <source>Cancer Discov</source>. <year>2017</year>;<volume>7</volume>(<issue>6</issue>):<fpage>620</fpage>‐<lpage>629</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-1250</pub-id>
<pub-id pub-id-type="pmid">28242752</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0009"><string-name><surname>Turner</surname><given-names>NC</given-names></string-name>, <string-name><surname>Telli</surname><given-names>ML</given-names></string-name>, <string-name><surname>Rugo</surname><given-names>HS</given-names></string-name>, et al. <article-title>A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)</article-title>. <source>Clin Cancer Res</source>. <year>2019</year>;<volume>25</volume>(<issue>9</issue>):<fpage>2717</fpage>‐<lpage>2724</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-1891</pub-id>
<pub-id pub-id-type="pmid">30563931</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0010"><string-name><surname>Litton</surname><given-names>JK</given-names></string-name>, <string-name><surname>Rugo</surname><given-names>HS</given-names></string-name>, <string-name><surname>Ettl</surname><given-names>J</given-names></string-name>, et al. <article-title>Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation</article-title>. <source>N Engl J Med</source>. <year>2018</year>;<volume>379</volume>(<issue>8</issue>):<fpage>753</fpage>‐<lpage>763</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1802905</pub-id>
<pub-id pub-id-type="pmid">30110579</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0011"><string-name><surname>Robson</surname><given-names>M</given-names></string-name>, <string-name><surname>Im</surname><given-names>SA</given-names></string-name>, <string-name><surname>Senkus</surname><given-names>E</given-names></string-name>, et al. <article-title>Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>377</volume>(<issue>6</issue>):<fpage>523</fpage>‐<lpage>533</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1706450</pub-id>
<pub-id pub-id-type="pmid">28578601</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0012"><string-name><surname>Abida</surname><given-names>W</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>D</given-names></string-name>, <string-name><surname>Patnaik</surname><given-names>A</given-names></string-name>, et al. <article-title>Non‐BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration‐resistant prostate cancer: analysis from the phase II TRITON2 study</article-title>. <source>Clin Cancer Res</source>. <year>2020</year>;<volume>26</volume>(<issue>11</issue>):<fpage>2487</fpage>‐<lpage>2496</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-0394</pub-id>
<pub-id pub-id-type="pmid">32086346</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0013"><string-name><surname>de Bono</surname><given-names>J</given-names></string-name>, <string-name><surname>Mateo</surname><given-names>J</given-names></string-name>, <string-name><surname>Fizazi</surname><given-names>K</given-names></string-name>, et al. <article-title>Olaparib for metastatic castration‐resistant prostate cancer</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>(<issue>22</issue>):<fpage>2091</fpage>‐<lpage>2102</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1911440</pub-id>
<pub-id pub-id-type="pmid">32343890</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0014"><string-name><surname>Golan</surname><given-names>T</given-names></string-name>, <string-name><surname>Hammel</surname><given-names>P</given-names></string-name>, <string-name><surname>Reni</surname><given-names>M</given-names></string-name>, et al. <article-title>Maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer</article-title>. <source>N Engl J Med</source>. <year>2019</year>;<volume>381</volume>(<issue>4</issue>):<fpage>317</fpage>‐<lpage>327</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1903387</pub-id>
<pub-id pub-id-type="pmid">31157963</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0015"><string-name><surname>Mirza</surname><given-names>MR</given-names></string-name>, <string-name><surname>Monk</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Herrstedt</surname><given-names>J</given-names></string-name>, et al. <article-title>Niraparib maintenance therapy in platinum‐sensitive, recurrent ovarian cancer</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>375</volume>(<issue>22</issue>):<fpage>2154</fpage>‐<lpage>2164</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1611310</pub-id>
<pub-id pub-id-type="pmid">27717299</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0016"><string-name><surname>Moore</surname><given-names>KN</given-names></string-name>, <string-name><surname>Secord</surname><given-names>AA</given-names></string-name>, <string-name><surname>Geller</surname><given-names>MA</given-names></string-name>, et al. <article-title>Niraparib monotherapy for late‐line treatment of ovarian cancer (QUADRA): a multicentre, open‐label, single‐arm, phase 2 trial</article-title>. <source>Lancet Oncol</source>. <year>2019</year>;<volume>20</volume>(<issue>5</issue>):<fpage>636</fpage>‐<lpage>648</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(19)30029-4</pub-id>
<pub-id pub-id-type="pmid">30948273</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0017"><string-name><surname>Oza</surname><given-names>AM</given-names></string-name>, <string-name><surname>Tinker</surname><given-names>AV</given-names></string-name>, <string-name><surname>Oaknin</surname><given-names>A</given-names></string-name>, et al. <article-title>Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high‐grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2</article-title>. <source>Gynecol Oncol</source>. <year>2017</year>;<volume>147</volume>(<issue>2</issue>):<fpage>267</fpage>‐<lpage>275</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ygyno.2017.08.022</pub-id>
<pub-id pub-id-type="pmid">28882436</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0018"><string-name><surname>Pujade‐Lauraine</surname><given-names>E</given-names></string-name>, <string-name><surname>Ledermann</surname><given-names>JA</given-names></string-name>, <string-name><surname>Selle</surname><given-names>F</given-names></string-name>, et al. <article-title>Olaparib tablets as maintenance therapy in patients with platinum‐sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT‐Ov21): a double‐blind, randomised, placebo‐controlled, phase 3 trial</article-title>. <source>Lancet Oncol</source>. <year>2017</year>;<volume>18</volume>(<issue>9</issue>):<fpage>1274</fpage>‐<lpage>1284</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(17)30469-2</pub-id>
<pub-id pub-id-type="pmid">28754483</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0019"><string-name><surname>Swisher</surname><given-names>EM</given-names></string-name>, <string-name><surname>Lin</surname><given-names>KK</given-names></string-name>, <string-name><surname>Oza</surname><given-names>AM</given-names></string-name>, et al. <article-title>Rucaparib in relapsed, platinum‐sensitive high‐grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open‐label, phase 2 trial</article-title>. <source>Lancet Oncol</source>. <year>2017</year>;<volume>18</volume>(<issue>1</issue>):<fpage>75</fpage>‐<lpage>87</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(16)30559-9</pub-id>
<pub-id pub-id-type="pmid">27908594</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0020"><string-name><surname>de Bono</surname><given-names>JS</given-names></string-name>, <string-name><surname>Mehra</surname><given-names>N</given-names></string-name>, <string-name><surname>Scagliotti</surname><given-names>GV</given-names></string-name>, et al. <article-title>Talazoparib monotherapy in metastatic castration‐resistant prostate cancer with DNA repair alterations (TALAPRO‐1): an open‐label, phase 2 trial</article-title>. <source>Lancet Oncol</source>. <year>2021</year>;<volume>22</volume>(<issue>9</issue>):<fpage>1250</fpage>‐<lpage>1264</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(21)00376-4</pub-id>
<pub-id pub-id-type="pmid">34388386</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0021"><string-name><surname>Calabrese</surname><given-names>CR</given-names></string-name>, <string-name><surname>Almassy</surname><given-names>R</given-names></string-name>, <string-name><surname>Barton</surname><given-names>S</given-names></string-name>, et al. <article-title>Anticancer chemosensitization and radiosensitization by the novel poly(ADP‐ribose) polymerase‐1 inhibitor AG14361</article-title>. <source>J Natl Cancer Inst</source>. <year>2004</year>;<volume>96</volume>(<issue>1</issue>):<fpage>56</fpage>‐<lpage>67</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djh005</pub-id>
<pub-id pub-id-type="pmid">14709739</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0022"><string-name><surname>Donawho</surname><given-names>CK</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y</given-names></string-name>, et al. <article-title>ABT‐888, an orally active poly(ADP‐ribose) polymerase inhibitor that potentiates DNA‐damaging agents in preclinical tumor models</article-title>. <source>Clin Cancer Res</source>. <year>2007</year>;<volume>13</volume>(<issue>9</issue>):<fpage>2728</fpage>‐<lpage>2737</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-3039</pub-id>
<pub-id pub-id-type="pmid">17473206</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0023"><string-name><surname>Byers</surname><given-names>LA</given-names></string-name>, <string-name><surname>Nilsson</surname><given-names>M</given-names></string-name>, <string-name><surname>Fujimoto</surname><given-names>J</given-names></string-name>, et al. <article-title>Investigation of poly (Adp‐Ribose) polymerase 1 (Parp1) as a novel therapeutic target in Small Cell Lung Cancer (Sclc)</article-title>. <source>J Thorac Oncol</source>. <year>2011</year>;<volume>6</volume>(<issue>6</issue>):<fpage>S1530</fpage>‐<lpage>S1531</lpage>.</mixed-citation>
              </ref>
              <ref id="cam44724-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0024"><string-name><surname>Salemi</surname><given-names>M</given-names></string-name>, <string-name><surname>Galia</surname><given-names>A</given-names></string-name>, <string-name><surname>Fraggetta</surname><given-names>F</given-names></string-name>, et al. <article-title>Poly (ADP‐ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue</article-title>. <source>Eur J Histochem</source>. <year>2013</year>;<volume>57</volume>(<issue>2</issue>):<fpage>e13</fpage>. doi:<pub-id pub-id-type="doi">10.4081/ejh.2013.e13</pub-id><pub-id pub-id-type="pmid">23807292</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0025"><string-name><surname>Ossovskaya</surname><given-names>V</given-names></string-name>, <string-name><surname>Koo</surname><given-names>IC</given-names></string-name>, <string-name><surname>Kaldjian</surname><given-names>EP</given-names></string-name>, <string-name><surname>Alvares</surname><given-names>C</given-names></string-name>, <string-name><surname>Sherman</surname><given-names>BM</given-names></string-name>. <article-title>Upregulation of Poly (ADP‐Ribose) Polymerase‐1 (PARP1) in triple‐negative breast cancer and other primary human tumor types</article-title>. <source>Genes Cancer</source>. <year>2010</year>;<volume>1</volume>(<issue>8</issue>):<fpage>812</fpage>‐<lpage>821</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1947601910383418</pub-id>
<pub-id pub-id-type="pmid">21779467</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0026"><string-name><surname>Bieche</surname><given-names>I</given-names></string-name>, <string-name><surname>de Murcia</surname><given-names>G</given-names></string-name>, <string-name><surname>Lidereau</surname><given-names>R</given-names></string-name>. <article-title>Poly(ADP‐ribose) polymerase gene expression status and genomic instability in human breast cancer</article-title>. <source>Clin Cancer Res</source>. <year>1996</year>;<volume>2</volume>(<issue>7</issue>):<fpage>1163</fpage>‐<lpage>1167</lpage>.<pub-id pub-id-type="pmid">9816283</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0027"><string-name><surname>LoRusso</surname><given-names>PM</given-names></string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name>, <string-name><surname>Burger</surname><given-names>A</given-names></string-name>, et al. <article-title>Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP‐ribose) Polymerase (PARP) Inhibitor Veliparib (ABT‐888) in Combination with Irinotecan in Patients with Advanced Solid Tumors</article-title>. <source>Clin Cancer Res</source>. <year>2016</year>;<volume>22</volume>(<issue>13</issue>):<fpage>3227</fpage>‐<lpage>3237</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-0652</pub-id>
<pub-id pub-id-type="pmid">26842236</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0028"><string-name><surname>Rajan</surname><given-names>A</given-names></string-name>, <string-name><surname>Carter</surname><given-names>CA</given-names></string-name>, <string-name><surname>Kelly</surname><given-names>RJ</given-names></string-name>, et al. <article-title>A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors</article-title>. <source>Clin Cancer Res</source>. <year>2012</year>;<volume>18</volume>(<issue>8</issue>):<fpage>2344</fpage>‐<lpage>2351</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2425</pub-id>
<pub-id pub-id-type="pmid">22371451</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0029"><string-name><surname>Lee</surname><given-names>JM</given-names></string-name>, <string-name><surname>Hays</surname><given-names>JL</given-names></string-name>, <string-name><surname>Annunziata</surname><given-names>CM</given-names></string-name>, et al. <article-title>Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation‐associated breast or ovarian cancer with biomarker analyses</article-title>. <source>J Natl Cancer Inst</source>. <year>2014</year>;<volume>106</volume>(<issue>6</issue>):<fpage>dju089</fpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/dju089</pub-id><pub-id pub-id-type="pmid">24842883</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0030"><string-name><surname>Dent</surname><given-names>RA</given-names></string-name>, <string-name><surname>Lindeman</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Clemons</surname><given-names>M</given-names></string-name>, et al. <article-title>Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first‐ or second‐line treatment of patients with metastatic triple‐negative breast cancer</article-title>. <source>Breast Cancer Res</source>. <year>2013</year>;<volume>15</volume>(<issue>5</issue>):<fpage>R88</fpage>. doi:<pub-id pub-id-type="doi">10.1186/bcr3484</pub-id><pub-id pub-id-type="pmid">24063698</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0031"><string-name><surname>Dhawan</surname><given-names>MS</given-names></string-name>, <string-name><surname>Bartelink</surname><given-names>IH</given-names></string-name>, <string-name><surname>Aggarwal</surname><given-names>RR</given-names></string-name>, et al. <article-title>Differential toxicity in patients with and without DNA repair mutations: phase I study of carboplatin and talazoparib in advanced solid tumors</article-title>. <source>Clin Cancer Res</source>. <year>2017</year>;<volume>23</volume>(<issue>21</issue>):<fpage>6400</fpage>‐<lpage>6410</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-0703</pub-id>
<pub-id pub-id-type="pmid">28790114</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0032"><string-name><surname>Appleman</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Beumer</surname><given-names>JH</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>Y</given-names></string-name>, et al. <article-title>Phase 1 study of veliparib (ABT‐888), a poly (ADP‐ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2019</year>;<volume>84</volume>(<issue>6</issue>):<fpage>1289</fpage>‐<lpage>1301</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00280-019-03960-w</pub-id>
<pub-id pub-id-type="pmid">31549216</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0033"><string-name><surname>Rivkin</surname><given-names>SE</given-names></string-name>, <string-name><surname>Moon</surname><given-names>J</given-names></string-name>, <string-name><surname>Iriarte</surname><given-names>DS</given-names></string-name>, et al. <article-title>Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients</article-title>. <source>Int J Gynecol Cancer</source>. <year>2019</year>;<volume>29</volume>(<issue>2</issue>):<fpage>325</fpage>‐<lpage>333</lpage>. doi:<pub-id pub-id-type="doi">10.1136/ijgc-2018-000035</pub-id>
<pub-id pub-id-type="pmid">30700568</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0034"><string-name><surname>Bendell</surname><given-names>J</given-names></string-name>, <string-name><surname>O'Reilly</surname><given-names>EM</given-names></string-name>, <string-name><surname>Middleton</surname><given-names>MR</given-names></string-name>, et al. <article-title>Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer</article-title>. <source>Ann Oncol</source>. <year>2015</year>;<volume>26</volume>(<issue>4</issue>):<fpage>804</fpage>‐<lpage>811</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdu581</pub-id>
<pub-id pub-id-type="pmid">25573533</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0035"><string-name><surname>Rottenberg</surname><given-names>S</given-names></string-name>, <string-name><surname>Jaspers</surname><given-names>JE</given-names></string-name>, <string-name><surname>Kersbergen</surname><given-names>A</given-names></string-name>, et al. <article-title>High sensitivity of BRCA1‐deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2008</year>;<volume>105</volume>(<issue>44</issue>):<fpage>17079</fpage>‐<lpage>17084</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0806092105</pub-id>
<pub-id pub-id-type="pmid">18971340</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0036"><string-name><surname>Chan</surname><given-names>JK</given-names></string-name>, <string-name><surname>Brady</surname><given-names>MF</given-names></string-name>, <string-name><surname>Penson</surname><given-names>RT</given-names></string-name>, et al. <article-title>Weekly vs. Every‐3‐week paclitaxel and carboplatin for ovarian cancer</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>374</volume>(<issue>8</issue>):<fpage>738</fpage>‐<lpage>748</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1505067</pub-id>
<pub-id pub-id-type="pmid">26933849</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0037"><string-name><surname>Vokes</surname><given-names>EE</given-names></string-name>, <string-name><surname>Stenson</surname><given-names>K</given-names></string-name>, <string-name><surname>Rosen</surname><given-names>FR</given-names></string-name>, et al. <article-title>Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ‐preserving therapy for advanced head and neck cancer</article-title>. <source>J Clin Oncol</source>. <year>2003</year>;<volume>21</volume>(<issue>2</issue>):<fpage>320</fpage>‐<lpage>326</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2003.06.006</pub-id>
<pub-id pub-id-type="pmid">12525525</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0038"><string-name><surname>Belani</surname><given-names>CP</given-names></string-name>, <string-name><surname>Ramalingam</surname><given-names>S</given-names></string-name>, <string-name><surname>Perry</surname><given-names>MC</given-names></string-name>, et al. <article-title>Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every‐3‐weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non‐small‐cell lung cancer</article-title>. <source>J Clin Oncol</source>. <year>2008</year>;<volume>26</volume>(<issue>3</issue>):<fpage>468</fpage>‐<lpage>473</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2007.13.1912</pub-id>
<pub-id pub-id-type="pmid">18202422</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0039"><string-name><surname>Keresztes</surname><given-names>RS</given-names></string-name>, <string-name><surname>Port</surname><given-names>JL</given-names></string-name>, <string-name><surname>Pasmantier</surname><given-names>MW</given-names></string-name>, <string-name><surname>Korst</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Altorki</surname><given-names>NK</given-names></string-name>. <article-title>Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2003</year>;<volume>126</volume>(<issue>5</issue>):<fpage>1603</fpage>‐<lpage>1608</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0022-5223(03)00710-4</pub-id>
<pub-id pub-id-type="pmid">14666040</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0040"><string-name><surname>Fountzilas</surname><given-names>G</given-names></string-name>, <string-name><surname>Kalofonos</surname><given-names>HP</given-names></string-name>, <string-name><surname>Dafni</surname><given-names>U</given-names></string-name>, et al. <article-title>Paclitaxel and epirubicin versus paclitaxel and carboplatin as first‐line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group</article-title>. <source>Ann Oncol</source>. <year>2004</year>;<volume>15</volume>(<issue>10</issue>):<fpage>1517</fpage>‐<lpage>1526</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdh395</pub-id>
<pub-id pub-id-type="pmid">15367413</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0041"><string-name><surname>Vaughn</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Manola</surname><given-names>J</given-names></string-name>, <string-name><surname>Dreicer</surname><given-names>R</given-names></string-name>, <string-name><surname>See</surname><given-names>W</given-names></string-name>, <string-name><surname>Levitt</surname><given-names>R</given-names></string-name>, <string-name><surname>Wilding</surname><given-names>G</given-names></string-name>. <article-title>Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group</article-title>. <source>Cancer</source>. <year>2002</year>;<volume>95</volume>(<issue>5</issue>):<fpage>1022</fpage>‐<lpage>1027</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.10782</pub-id>
<pub-id pub-id-type="pmid">12209686</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0042"><string-name><surname>Pignata</surname><given-names>S</given-names></string-name>, <string-name><surname>Scambia</surname><given-names>G</given-names></string-name>, <string-name><surname>Katsaros</surname><given-names>D</given-names></string-name>, et al. <article-title>Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO‐7): a randomised, multicentre, open‐label, phase 3 trial</article-title>. <source>Lancet Oncol</source>. <year>2014</year>;<volume>15</volume>(<issue>4</issue>):<fpage>396</fpage>‐<lpage>405</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(14)70049-X</pub-id>
<pub-id pub-id-type="pmid">24582486</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0043"><string-name><surname>Katsumata</surname><given-names>N</given-names></string-name>, <string-name><surname>Yasuda</surname><given-names>M</given-names></string-name>, <string-name><surname>Isonishi</surname><given-names>S</given-names></string-name>, et al. <article-title>Long‐term results of dose‐dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open‐label trial</article-title>. <source>Lancet Oncol</source>. <year>2013</year>;<volume>14</volume>(<issue>10</issue>):<fpage>1020</fpage>‐<lpage>1026</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(13)70363-2</pub-id>
<pub-id pub-id-type="pmid">23948349</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0044"><string-name><surname>Sparano</surname><given-names>JA</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>Martino</surname><given-names>S</given-names></string-name>, et al. <article-title>Weekly paclitaxel in the adjuvant treatment of breast cancer</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>358</volume>(<issue>16</issue>):<fpage>1663</fpage>‐<lpage>1671</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa0707056</pub-id>
<pub-id pub-id-type="pmid">18420499</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0045"><string-name><surname>Khan</surname><given-names>OA</given-names></string-name>, <string-name><surname>Gore</surname><given-names>M</given-names></string-name>, <string-name><surname>Lorigan</surname><given-names>P</given-names></string-name>, et al. <article-title>A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours</article-title>. <source>Br J Cancer</source>. <year>2011</year>;<volume>104</volume>(<issue>5</issue>):<fpage>750</fpage>‐<lpage>755</lpage>. doi:<pub-id pub-id-type="doi">10.1038/bjc.2011.8</pub-id>
<pub-id pub-id-type="pmid">21326243</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="miscellaneous" id="cam44724-cit-0046"><string-name><surname>Pfizer</surname>, <given-names>Inc</given-names></string-name>. <collab collab-type="authors">Talazoparib (Talzenna) [package insert]</collab>
. <article-title>U.S. Food and Drug Administration website</article-title>. <ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211651s007lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211651s007lbl.pdf</ext-link>. Revised September 2021. Accessed September 18, 2021.</mixed-citation>
              </ref>
              <ref id="cam44724-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0047"><string-name><surname>Eisenhauer</surname><given-names>EA</given-names></string-name>, <string-name><surname>Therasse</surname><given-names>P</given-names></string-name>, <string-name><surname>Bogaerts</surname><given-names>J</given-names></string-name>, et al. <article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title>. <source>Eur J Cancer</source>. <year>2009</year>;<volume>45</volume>(<issue>2</issue>):<fpage>228</fpage>‐<lpage>247</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id>
<pub-id pub-id-type="pmid">19097774</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0048"><string-name><surname>Le Tourneau</surname><given-names>C</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Siu</surname><given-names>LL</given-names></string-name>. <article-title>Dose escalation methods in phase I cancer clinical trials</article-title>. <source>J Natl Cancer Inst</source>. <year>2009</year>;<volume>101</volume>(<issue>10</issue>):<fpage>708</fpage>‐<lpage>720</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djp079</pub-id>
<pub-id pub-id-type="pmid">19436029</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0049">
                <label>49</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0049"><string-name><surname>Fong</surname><given-names>PC</given-names></string-name>, <string-name><surname>Boss</surname><given-names>DS</given-names></string-name>, <string-name><surname>Yap</surname><given-names>TA</given-names></string-name>, et al. <article-title>Inhibition of poly(ADP‐ribose) polymerase in tumors from BRCA mutation carriers</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>361</volume>(<issue>2</issue>):<fpage>123</fpage>‐<lpage>134</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa0900212</pub-id>
<pub-id pub-id-type="pmid">19553641</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0050">
                <label>50</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0050"><string-name><surname>Robson</surname><given-names>M</given-names></string-name>, <string-name><surname>Goessl</surname><given-names>C</given-names></string-name>, <string-name><surname>Domchek</surname><given-names>S</given-names></string-name>. <article-title>Olaparib for metastatic germline BRCA‐mutated breast cancer</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>377</volume>(<issue>18</issue>):<fpage>1792</fpage>‐<lpage>1793</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMc1711644</pub-id>
</mixed-citation>
              </ref>
              <ref id="cam44724-bib-0051">
                <label>51</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0051"><string-name><surname>Matulonis</surname><given-names>UA</given-names></string-name>, <string-name><surname>Penson</surname><given-names>RT</given-names></string-name>, <string-name><surname>Domchek</surname><given-names>SM</given-names></string-name>, et al. <article-title>Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety</article-title>. <source>Ann Oncol</source>. <year>2016</year>;<volume>27</volume>(<issue>6</issue>):<fpage>1013</fpage>‐<lpage>1019</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdw133</pub-id>
<pub-id pub-id-type="pmid">26961146</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0052">
                <label>52</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0052"><string-name><surname>Kaufman</surname><given-names>B</given-names></string-name>, <string-name><surname>Shapira‐Frommer</surname><given-names>R</given-names></string-name>, <string-name><surname>Schmutzler</surname><given-names>RK</given-names></string-name>, et al. <article-title>Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation</article-title>. <source>J Clin Oncol</source>. <year>2015</year>;<volume>33</volume>(<issue>3</issue>):<fpage>244</fpage>‐<lpage>250</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2014.56.2728</pub-id>
<pub-id pub-id-type="pmid">25366685</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0053">
                <label>53</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0053"><string-name><surname>Lord</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Ashworth</surname><given-names>A</given-names></string-name>. <article-title>BRCAness revisited</article-title>. <source>Nat Rev Cancer</source>. <year>2016</year>;<volume>16</volume>(<issue>2</issue>):<fpage>110</fpage>‐<lpage>120</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrc.2015.21</pub-id>
<pub-id pub-id-type="pmid">26775620</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0054">
                <label>54</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0054"><string-name><surname>Tung</surname><given-names>NM</given-names></string-name>, <string-name><surname>Robson</surname><given-names>ME</given-names></string-name>, <string-name><surname>Ventz</surname><given-names>S</given-names></string-name>, et al. <article-title>TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination‐related genes</article-title>. <source>J Clin Oncol</source>. <year>2020</year>;<volume>38</volume>(<issue>36</issue>):<fpage>4274</fpage>‐<lpage>4282</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.20.02151</pub-id>
<pub-id pub-id-type="pmid">33119476</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0055">
                <label>55</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0055"><string-name><surname>Hussain</surname><given-names>M</given-names></string-name>, <string-name><surname>Mateo</surname><given-names>J</given-names></string-name>, <string-name><surname>Fizazi</surname><given-names>K</given-names></string-name>, et al. <article-title>Survival with olaparib in metastatic castration‐resistant prostate cancer</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>383</volume>(<issue>24</issue>):<fpage>2345</fpage>‐<lpage>2357</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2022485</pub-id>
<pub-id pub-id-type="pmid">32955174</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0056">
                <label>56</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0056"><string-name><surname>Coleman</surname><given-names>RL</given-names></string-name>, <string-name><surname>Fleming</surname><given-names>GF</given-names></string-name>, <string-name><surname>Brady</surname><given-names>MF</given-names></string-name>, et al. <article-title>Veliparib with first‐line chemotherapy and as maintenance therapy in ovarian cancer</article-title>. <source>N Engl J Med</source>. <year>2019</year>;<volume>381</volume>(<issue>25</issue>):<fpage>2403</fpage>‐<lpage>2415</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1909707</pub-id>
<pub-id pub-id-type="pmid">31562800</pub-id></mixed-citation>
              </ref>
              <ref id="cam44724-bib-0057">
                <label>57</label>
                <mixed-citation publication-type="journal" id="cam44724-cit-0057"><string-name><surname>Dieras</surname><given-names>V</given-names></string-name>, <string-name><surname>Han</surname><given-names>HS</given-names></string-name>, <string-name><surname>Kaufman</surname><given-names>B</given-names></string-name>, et al. <article-title>Veliparib with carboplatin and paclitaxel in BRCA‐mutated advanced breast cancer (BROCADE3): a randomised, double‐blind, placebo‐controlled, phase 3 trial</article-title>. <source>Lancet Oncol</source>. <year>2020</year>;<volume>21</volume>(<issue>10</issue>):<fpage>1269</fpage>‐<lpage>1282</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(20)30447-2</pub-id>
<pub-id pub-id-type="pmid">32861273</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
